Table 1. Protective efficacies of MSP119-BBVs against challenge infectiona.
| Vaccine (Challenge parasite) | Mouse strain | Route | Anti-MSP119 titerb mean±SE | No. of protected mice/total no. (%) |
| EXP1 (Pb-PfM19) | ||||
| G1: Non-immunized | BALB/c | - | NDc | 0/5 (0) |
| G2: GST-PfMSP1+alum | BALB/c | i.p. | 134,000±28,600 | 0/5 (0) |
| G3: AcNPV-WT | BALB/c | i.m. | ND | 0/5 (0) |
| G4: AcNPV-PfMSP119surf | BALB/c | i.m. | 72,600±19,300 | 0/5 (0) |
| G5: AcNPV-PfMSP119surf | BALB/c | i.n. | 167,000±47,300 | 0/5 (0) |
| EXP2 (P. yoelii) | ||||
| G1: Non-immunize | BALB/c | - | ND | 1/10 (10) |
| G2: GST-PyMSP119+alum | BALB/c | i.p. | 171,000±138,000 | 7/10 (70) |
| G3: AcNPV-WT | BALB/c | i.m. | ND | 0/10 (0) |
| G4: AcNPV-PyMSP119surf | BALB/c | i.m. | 159,000±55,700 | 5/10 (50) |
| G5: AcNPV-PyMSP119surf | BALB/c | i.n. | 126,000±33,900 | 10/10 (100) |
| EXP3 (P. berghei) | ||||
| G1: Non-immunize | BALB/c | - | ND | 0/5 (0) |
| G2: GST-PbMSP119+alum | BALB/c | i.p. | 256,000±55,000 | 0/10 (0) |
| G3: AcNPV-WT | BALB/c | i.m. | ND | 0/5 (0) |
| G4: AcNPV-PbMSP119surf | BALB/c | i.m. | 103,000±31,700 | 0/5 (0) |
| G5: AcNPV-PbMSP119surf | BALB/c | i.n. | 97,800±49,800 | 0/10 (0) |
| G6: Non-immunize | C57/BL6 | - | ND | 0/5 (0) |
| G7: AcNPV-WT | C57/BL6 | i.m. | ND | 0/5 (0) |
| G8: AcNPV-PbMSP119surf | C57/BL6 | i.m. | 88,100±8,590 | 0/5 (0) |
a
Groups of mice were immunized with MSP119-BBVs three times and challenged either with Pb-PfMSP19, P. yoelii or P. berghei following blood collection for ELISA.
b
Levels of PfMSP119-, PyMSP119- and PbMSP119- specific IgG for EXP1, 2 and 3, respectively, were measured by ELISA.
c
ND, not detectable level (<500).